McCune-Albright syndrome combined with gigantism：clinical characteristics and long-term follow-up.

doi:10.7504/nk2014050403

McCune-Albright syndrome combined with gigantism：clinical characteristics and long-term follow-up.

XU Ling-ling，ZHU Hui-juan，LI Mei，WANG Ou，JIANG Yan，ZHANG Hua-bing，CHAI Xiao-feng，FENG Kai，LI Nai-shi，MAO Jiang-feng，TONG An-li，WANG Lin-jie，LIU Wei，GU Feng.

Department of Endocrinology，Key Laboratory of Endocrinology of the Ministry of Health，Peking Union Medical College Hospital，Chinese Academy of Medical Sciences，Beijing 100730,China

Online:2014-06-01 Published:2014-06-03

McCune-Albright综合征伴巨人症临床特点及长期随访研究

许岭翎，朱惠娟，李梅，王鸥，姜艳，张化冰，柴晓峰冯凯，李乃适，茅江峰，童安莉，王林杰，刘巍，顾锋

作者单位：中国医学科学院北京协和医学院北京协和医院内分泌科卫生部内分泌重点实验室，北京 100730

通讯作者: 顾锋
基金资助:
国家临床重点专科建设项目(WBYZ2011873)

Abstract

Abstract:

Abstract：Objective To investigate the clinical characteristics，causes of disease and responses to treatment in McCune-Albright syndrome patients combined with gigantism.Methods Long-term follow-up were performed on two cases of McCune-Albright syndrome combined with gigantism，and in combination with literatures the clinical characteristics were analyzed and discussed.Results Both patients underwent neuronavigator assisted transsphenoidal resection of pituitary tumor.After operation，the levels of GH and IGF-1 were significantly decreased.In case 2，GH and IGF-1 levels returned to normal without recurrence during 3-year follow-up.In case 1，treatment of bromocriptine and long-acting somatostatin were performed；growth was notably inhibited and the levels of GH and IGF-1 were significantly decreased.Both patients received bisphosphonate therapy，and bone lesion progression was effectively controlled.Both patients were diagnosed with hypogonadism at the follow-up.Conclusion Treatment of this disease is a long procedure.Clinician should select individualized and comprehensive treatment measures according to the characteristics of patients.Neuronavigation in transsphenoidal resection of pituitary adenoma operation，long-acting somatostatin and bisphosphonate therapy are important measures to control the disease.

Key words: gigantism, McCune-Albright syndrome, somatostatin, bisphosphonate

摘要：

目的探讨伴有巨人症的McCune-Albright综合征患者的临床特点、病程以及对治疗的反应。方法长期随访北京协和医院收治的2例伴有巨人症的McCune-Albright综合征患者的临床治疗及实验室检查情况。结果 2例患者均接受了神经导航下经蝶入路垂体瘤切除手术，术后生长激素(GH)、胰岛素样生长因子-1(IGF-1)均明显下降，其中例2完全降至正常，随诊3年未见垂体瘤复发迹象；例1术后接受了溴隐亭和长效生长抑素的治疗，生长速度明显降低，GH和IGF-1下降。2例患者均接受了双膦酸盐治疗，骨骼病变进展均得到了有效控制。2例患者均在病程中出现了性腺功能减退。结论治疗是一个长期的过程，需要临床医生根据患者的特点决定，采用个体化的综合治疗措施。神经导航下经蝶入路垂体瘤切除手术、长效生长抑素和双膦酸盐是控制本病的重要措施。

关键词: 巨人症, McCune-Albright综合征, 生长抑素, 双膦酸盐

CLC Number:

R394.3

XU Ling-ling，ZHU Hui-juan，LI Mei，WANG Ou，JIANG Yan，ZHANG Hua-bing，CHAI Xiao-feng，FENG Kai，LI Nai-shi，MAO Jiang-feng，TONG An-li，WANG Lin-jie，LIU Wei，GU Feng.. McCune-Albright syndrome combined with gigantism：clinical characteristics and long-term follow-up.[J]. Acta Metallurgica Sinica, DOI: 10.7504/nk2014050403.

许岭翎，朱惠娟，李梅，王鸥，姜艳，张化冰，柴晓峰冯凯，李乃适，茅江峰，童安莉，王林杰，刘巍，顾锋. McCune-Albright综合征伴巨人症临床特点及长期随访研究[J]. 中国实用内科杂志, DOI: 10.7504/nk2014050403.

References

［1］Akintoye SO，Cheli C，Booher S，et al.Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome［J］.J Clin Endocrinol Metab，2002，87(11)：5104-5112.

［2］Tajima T，Tsubaki J，Ishizu K，et al.Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism：effect of ostreotide-long acting release(LAR) and cabergoline therapy［J］.Endocrine J，2008，55(3)：595-599.

［3］Lauberg MRP，Hoejberg AS，Brock-Jacobsen B.Pegvisomant therapy in pituitary gigantism：successful treatment in 12-year-old girl［J］.Eur J Endocrinol，2005，153(2)：195-201.

［4］Albright F，Butler AM，Hampton AO，et al.Syndrome characterized by osteitis fibrosa disseminata，areas of pigmentation and endocrine dysfunction，with precocious puberty in females.N Engl J Med，1937，216(4)：727-746.

［5］Diaz A，Danon M，Crawford J.McCune-Albright syndrome and disorders due to activating mutations of GNAS1［J］.J Pediatr Endocrinol Metab，2007，20(8)：853-880.

［6］Vortmeyer AO，Glasker S，Mehta GU，et al.Somatic GNAS mutation causes widespread diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome［J］.J Clin Endocrinol Metab，2012，97(7)：2404-2413.

［7］Leet AI，Chebli C，Kushner H，et al.Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome［J］.J Bone Miner Res，2004，19(4)：571-577.

［8］Plotkin H，Rauch F，Zeitlin N，et al.Effect of Pamidronate treatment in children with polyostotic fibrous dysplasia of bone［J］.J Clin Endocrinol Metab，2003，88(10)：4569-4575.

［9］李梅，邢小平，夏维波等.合并甲状腺功能亢进症的两例McCune-Albright 综合征患者临床特点及药物治疗析评［J］.中华骨质疏松和骨矿盐疾病杂志，2009，2(1)：65-69.

［10］Bhansali A，Sharma BS，Sreenivasulu P，et al.Acromegaly with fibrous dysplasia：McCune-Albright syndrome-clinical studies in 3 cases and brief review of literature.Endocr J，2003，50(6)：793-799.

［11］Dou W，Lin N，Ma W，et al.Transsphenoidal surgery in a patient with acromegaly and McCune-Albright syndrome：application of neuronavigation［J］.J Neurosurg，2008，108(1)：164-169.

［12］柳夫义，李文婷，窦万臣等.伴有垂体生长激素腺瘤的McCune-Albright 综合征一例并文献复习［J］.中华神经外科杂志，2009，25(1)：3-7.

［13］Akintoye S，Kelly MH，Brillante B，et al.Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright Syndrome［J］.J Clin Endocrinol Metab，2006，91(8)：2960-2966.

［14］Nozieres C，Berlier P，Dupuis C，et al.Sporadic and genetic forms of paediatric somatotropinoma：a retrospective analysis of seven cases and a review of the literature［J］.Orphanet J Rare Dis，2011，6(10)：67.

2013-12-16收稿 2014-03-15修回本文编辑：高森